Nine-Week Versus One-Year Trastuzumab for Early Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer: 10-Year Update of the ShortHER Phase III Randomized TrialPierFranco Conte, Valentina Guarneri, Elisa Anselmi et al.|Journal of Clinical Oncology|2023Cited by 25
Metastatic site patterns by intrinsic subtype and HER2DX in early HER2-positive breast cancerMaria Vittoria Dieci, Valentina Guarneri, PierFranco Conte et al.|JNCI Journal of the National Cancer Institute|2023Cited by 14